Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients.
OBJECTIVE
To assess intravitreal bevacizumab (IVB) for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in Japanese patients.


METHODS
Forty-seven patients treated with IVB for newly diagnosed subfoveal or juxtafoveal CNV (predominantly classic CNV, 15 eyes; minimally classic CNV, 11 eyes; occult CNV, 21 eyes) secondary to AMD and followed for more than 12 months were reviewed retrospectively. IVB (1 mg) was injected via the pars plana. Additional IVB or photodynamic therapy was administered for either persistent or recurrent exudation. The main outcome measurements were best-corrected visual acuity (BCVA), number of injections, and treatment other than bevacizumab.


RESULTS
The mean baseline visual acuity (VA) was 0.38 [logarithm of the minimum angle of resolution (logMAR), 0.42] and final VA was 0.42 (logMAR, 0.38). During 12 months, bevacizumab was injected a mean of 3.4 times. Eight eyes received additional treatment. Up until 12 months, the mean BCVA with predominantly classic CNV increased, whereas the BCVA with minimally classic or occult with no classic CNV stabilized. The mean number of injections for predominantly classic CNV was 2.5, that for minimally classic CNV was 4.9, and that for occult with no classic CNV was 3.3.


CONCLUSIONS
IVB was especially effective for predominantly classic CNV, but CNV with subretinal pigment epithelial lesions might recur or enlarge despite additional IVB.
Suzuki
Mihoko
M
Department of Ophthalmology, Osaka University Medical School, Yamadaoka, Suita, Japan.
Gomi
Fumi
F
Sawa
Miki
M
Tsujikawa
Motokazu
M
Sakaguchi
Hirokazu
H
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D044466:Asian People / Q000208:ethnology; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000208:ethnology / Q000209:etiology; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D007267:Injections; D007564:Japan / Q000453:epidemiology; D008268:Macular Degeneration / Q000150:complications* / Q000208:ethnology; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D019233:Retreatment; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green
Am J Ophthalmol. 2003 Dec;136(6):1049-61
14644215
Ophthalmology. 2008 Jan;115(1):141-6
17582498
Retina. 2005 Oct-Nov;25(7):815-27
16205558
Br J Ophthalmol. 1997 Feb;81(2):154-62
9059252
Am J Ophthalmol. 2007 Apr;143(4):566-83
17386270
Br J Ophthalmol. 2008 Jan;92(1):70-3
17567661
Hum Genet. 2006 Aug;120(1):139-43
16710702
Jpn J Ophthalmol. 2008 Mar-Apr;52(2):99-107
18626732
Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5
16156152
Retina. 2006 May-Jun;26(5):495-511
16770255
Eye (Lond). 2008 Jan;22(1):82-6
17891059
Am J Ophthalmol. 2008 Feb;145(2):249-256
18067876
Am J Ophthalmol. 2008 Feb;145(2):239-248
18222192
Acta Ophthalmol. 2008 Jun;86(4):372-6
18028234
N Engl J Med. 2006 Oct 5;355(14):1419-31
17021318
Arch Ophthalmol. 1984 Nov;102(11):1640-2
6208888
Br J Ophthalmol. 2008 Dec;92(12):1636-41
18782803
Endocr Rev. 1997 Feb;18(1):4-25
9034784
Am J Ophthalmol. 2007 Dec;144(6):850-857
17949673
N Engl J Med. 2004 Dec 30;351(27):2805-16
15625332
Retina. 2006 Apr;26(4):383-90
16603955
Retina. 2007 Apr-May;27(4):439-44
17420695